Navigation Links
ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
Date:11/25/2013

REDWOOD CITY, Calif., Nov. 25, 2013 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that it initiated the first cohort of patients with advanced solid tumors in a Phase 1 clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10). Based on extensive clinical and preclinical data, ARMO plans to develop this unique molecule for known indications and innovative applications including cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. 

"Since its founding in December 2012, ARMO raised $20 million in a Series A round, licensed the PEGylated human IL-10 polypeptide from Merck, purchased the Prevascar (rHuIL-10) assets from Renovo Ltd. and assembled an outstanding scientific team with remarkable depth and knowledge of IL-10 to bring AM0010 into the clinic in record time," said Beth Seidenberg, M.D., partner at Kleiner Perkins Caufield & Byers and a member of the ARMO board of directors. "We see enormous potential in the development of this promising molecule."

"Multiple studies have shown that AM0010 directly activates tumor specific CD8+ killer T lymphocytes, which completely eradicate large tumor masses while establishing a lasting anti-tumor immune surveillance and significantly reduce metastatic disease in preclinical models," said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO.  "We expect our exceptional momentum in advancing AM0010 into development to continue, with initiation of additional clinical studies potentially in fibrosis, homozygous familial hypercholesterolemia and other indications in 2014, and anticipate results from our first study as soon as mid-2014."

The Phase 1 clinical trial is designed to establish the safety and tolerability of AM0010 in patients with advanced solid tumors. Ad
'/>"/>

SOURCE ARMO BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)... , Sept. 30, 2014  According to their ... of cancer clinical trials is going through a ... and the work of the current clinical trial ... of ,next generation, clinical trials, which will ultimately ... The company has been recognized by ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... NEW YORK, Jan. 16, 2012 Reportlinker.com ... is available in its catalogue: ... Medical Devices to 2016 ... gives a thorough analysis of the refurbished ...
... Conn., Jan. 13, 2012 /PRNewswire-iReach/ -- Global Information, ... report, "Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape ... http://photos.prnewswire.com/prnh/20120113/CG35865 ) The Insulin Delivery ... 6% to Reach $11 Billion by 2017 ...
Cached Medicine Technology:The Market Outlook for Refurbished Medical Devices to 2016 2The Market Outlook for Refurbished Medical Devices to 2016 3The Market Outlook for Refurbished Medical Devices to 2016 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... finding from Duke Medicine suggests that some people who ... be hard-wired to gain weight when exposed to chronic ... estimated 13 percent of people, all of whom are ... could help them reduce heart disease with simple interventions ... , "Genetic susceptibility, psychosocial stress and metabolic factors act ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... be releasing both Raima Database Manager (RDM) products ... version 9.1 and RDM Server will be released ... RDM,s high availability by providing replication between RDM ... provide developers of embedded systems with an easy ...
... shortened course of radiation therapy for prostate cancer ... PSA response for early-stage prostate cancer and has ... to a March 15 study in the ... journal of the American Society for Radiation Oncology ...
... and getaway destinations are affected, studies find , , SUNDAY, March ... allergies can be a burden on a family,s finances and ... to be presented in Washington, D.C., at the annual meeting ... how these common conditions can have a wide impact on ...
... Manufacturers Association issued the following statement from its president ... to President Obama,s nomination of Dr. Margaret Hamburg as ... (FDA), his nomination of Dr. Joshua Sharfstein as Principal ... a White House Food Safety Working Group:"We applaud President ...
... have exams, even if they have problems, study finds, , , ... coverage, or no health care coverage, are less likely to ... according to a new study. , The finding stems from ... part in the National Health Interview Survey from 1997 through ...
... in health care recruiting and staffing. Individuals have the choice of ... working with an established Health Career Agents office. , ... ... Agents now has three ways for qualified individuals to get involved ...
Cached Medicine News:Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 2Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 3Health News:Early results favorable for 5-day radiation treatment of early stage prostate cancer 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:Grocery Manufacturers Association Statement Regarding President Obama's Nomination of FDA Commissioner 2Health News:Eye Care Checkups Tied to Insurance Status 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3
Philadelphia™ Collar - Plastazote® with plastic anterior and posterior reinforcements. Hook-and-pile closure straps. Chin cradle reduces rotation. Occipital and mandibular pieces may be int...
... a lightweight patient friendly brace utilizing the latest ... The Escort provides patients with a lightweight brace ... Superior comfort and improved patient compliance is the ... Escort Hip brace is the result of a ...
... Management Systems are designed and engineered to ... your patients. Innovative new options increase function ... on the most successful patented features of ... clamping disk design and the tremendous versatility ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Medicine Products: